Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Veligrotug · Lumvoa, VRDN-001

Monoclonal antibody · Antagonist of insulin-like growth factor-1 receptor (IGF1R) · developed by Viridian Therapeutics

Approved FDA, Jun 2026
VRDN Developer
2 Registered trials

What is Veligrotug?

Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor (IGF-1R) and blocks ligand-induced receptor autophosphorylation, inhibiting IGF-1R signaling. It is studied in thyroid eye disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lumvoa, VRDN-001, AVE-1642, veligrotrug (LUMVOA)
Drug type
Monoclonal antibody
Targets
insulin-like growth factor-1 receptor (IGF1R)
Mechanism
Antagonist of insulin-like growth factor-1 receptor (IGF1R)
Pathways
IGF-1R signaling, receptor autophosphorylation
Therapy area
Ophthalmology
Developer
Viridian Therapeutics Inc (VRDN)
FDA status
Approved as Lumvoa (June 26, 2026), BLA761530 · FDA label
UNII
Z9U2SS9ZC8

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07832136 Phase 4 Thyroid Eye Disease Not yet recruiting VRDN
NCT06179875 Phase 3 Thyroid Eye Disease Completed VRDN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Thyroid Eye Disease

Other drugs acting on IGF1R

More from Viridian Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VRDN page.

Follow VRDN, the company behind Veligrotug

See VRDN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRDN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.